ADMA Biologics, Inc. (ADMA)
ADMA BioLogics, Inc. is a biopharmaceutical company specializing in the development and commercialization of immunoglobulin and other plasma-derived therapies. Focused on providing targeted treatments for immune deficiencies and infectious diseases, the company operates manufacturing facilities and has a portfolio aimed at improving patient outcomes through innovative plasma-based biologics.
Company News
The global plasma derived medicine market is projected to grow from $17.24 billion in 2024 to $37.4 billion by 2034, driven by increasing demand for therapies treating rare and immune disorders, with North America currently dominating the market.
Several mid-cap medical and biotechnology stocks have outperformed the broader market in 2025, including Penumbra Inc, TransMedics Group Inc, and ADMA Biologics Inc. These companies have shown strong momentum, bullish analyst sentiment, and potential for continued upside.
The article discusses the First Trust Small Cap Growth AlphaDEX ETF (FYC), analyzing its performance, risk profile, and comparing it to other small-cap growth ETFs. It suggests that FYC is a reasonable option for investors seeking to outperform the small-cap growth market segment, but there are other potentially cheaper and lower-risk alternatives to consider.
Adma Biologics (ADMA) stock rose 0.82% in the latest market close, lagging the S&P 500's 1.08% gain. The company is expected to report earnings of $0.08 per share, representing a 500% year-over-year growth, and revenue of $87.03 million, up 44.75% from the prior-year quarter.
